We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human|
|ELISA (Capture)||1 Antibodies|
|Enzyme Immunoassay (EIA)||4 Antibodies|
|Flow Cytometry (FACS)||67 Antibodies|
|Immunocytochemistry (ICC)||3 Antibodies|
|Immunofluorescence (IF)||15 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||46 Antibodies|
|Immunohistochemistry (IHC)||44 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||2 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||45 Antibodies|
|Immunoprecipitation (IP)||14 Antibodies|
|Western Blotting (WB)||139 Antibodies|
|Antigen||Fms-Related tyrosine Kinase 3 (FLT3) Antibodies|
|Conjugate||This FLT3 antibody is conjugated to FITC Alternatives|
Flow Cytometry (FACS)
|Supplier||Log in to see|
Product Details anti-FLT3 AntibodyTarget Details FLT3 Application Details Handling Images
|Cross-Reactivity (Details)||Species reactivity (tested):Human.|
|Characteristics||Synonyms: FL cytokine receptor, STK1, Tyrosine-protein kinase receptor FLT3, Stem cell tyrosine kinase1|
|Purification||Protein-A Sepharose Chromatography of hybridoma supernatant.|
|Immunogen||Pro B-cell line, BV-173. Remarks: Hybridoma was established by fusion of mouse myeloma cell SP2/0 with Balb/cmouse splenocyte.|
Target Details FLT3Product Details anti-FLT3 Antibody Application Details Handling Images back to top
|Alternative Name||CD135 / FLT3 (FLT3 Antibody Abstract)|
|Background||CD135, also known as FLT3 or FLK2, is a receptor tyrosine kinase involved in the early steps of hematopoiesis. CD135 is expressed by immature hematopoietic cells and leukemia cells and is involved in the survival, proliferation, and differentiation of stem cells. Mutations in CD135 are also associated with the development of about one third of human acute myeloid leukemias (ALM) and B-lineage acute lymphocytic leukemias (ALL).Synonyms: FL cytokine receptor, STK1, Stem cell tyrosine kinase 1, Tyrosine-protein kinase receptor FLT3|
|Research Area||CD Antigens, Surface Receptors of Immune Cells|
Application DetailsProduct Details anti-FLT3 Antibody Target Details FLT3 Handling Images back to top
Flow Cytometry: 50 μg/mL (final concentration). Positive Control: THP-1 cells. Detailed procedure is provided in Protocols.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Protocol||Flow cytometric analysis for floating cellsWe usually use Fisher tubes or equivalents as reaction tubes for all step described below. 1) Wash the cells 3 times with washing buffer [PBS containing 2% fetal calf serum (FCS) and0. 1% NaN3]. 2) Resuspend the cells with washing buffer (5x10e6 cells/mL). 3) Add 50 µL of the cell suspension into each tube, and centrifuge at 500 x g for 1 minute atroom temperature (20~25°C). Remove supernatant by careful aspiration. 4) Add 10 µL of normal goat serum containing 1 mg/mL normal human IgG and 0. 1% NaN3or 20 µL of Clear Back (human Fc receptor blocking reagent) to the cell pellet after tapping. Mix well and incubate for 5 minutes at room temperature. 5) Add 40 µL of the primary antibody at the concentration of as suggest in theAPPLICATIONS diluted in the washing buffer. Mix well, and incubate for 30 minutes at roomtemperature (20~25°C). 6) Add 1 mL of the washing buffer followed by centrifugation at 500 x g for 1 minute at roomtemperature. Remove supernatant by careful aspiration. 7) Resuspend the cells with 500 µL of the washing buffer and analyze by a flow cytometer. Positive Control for Flow Cytometry: THP-1|
|Restrictions||For Research Use only|
HandlingProduct Details anti-FLT3 Antibody Target Details FLT3 Application Details Images back to top
|Buffer||PBS containing 1 % BSA as stabilizer and 0.09 % Sodium Azide as preservative.|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
Store the antibody undiluted at 2-8 °C.
Shelf life: one year from despatch.
|Expiry Date||12 months|
ImagesProduct Details anti-FLT3 Antibody Target Details FLT3 Application Details Handling back to top